Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Feb 29;25(5):2822.
doi: 10.3390/ijms25052822.

Exploring Epigenetic Modifications as Potential Biomarkers and Therapeutic Targets in Glaucoma

Emanuele Tonti  1 , Roberto Dell'Omo  2 , Mariaelena Filippelli  2 , Leopoldo Spadea  1 , Carlo Salati  3 , Caterina Gagliano  4   5 , Mutali Musa  6 , Marco Zeppieri  3
Affiliations
Review

Exploring Epigenetic Modifications as Potential Biomarkers and Therapeutic Targets in Glaucoma

Emanuele Tonti et al. Int J Mol Sci. .

Abstract

Glaucoma, a complex and multifactorial neurodegenerative disorder, is a leading cause of irreversible blindness worldwide. Despite significant advancements in our understanding of its pathogenesis and management, early diagnosis and effective treatment of glaucoma remain major clinical challenges. Epigenetic modifications, encompassing deoxyribonucleic acid (DNA) methylation, histone modifications, and non-coding RNAs, have emerged as critical regulators of gene expression and cellular processes. The aim of this comprehensive review focuses on the emerging field of epigenetics and its role in understanding the complex genetic and molecular mechanisms underlying glaucoma. The review will provide an overview of the pathophysiology of glaucoma, emphasizing the intricacies of intraocular pressure regulation, retinal ganglion cell dysfunction, and optic nerve damage. It explores how epigenetic modifications, such as DNA methylation and histone modifications, can influence gene expression, and how these mechanisms are implicated in glaucomatous neurodegeneration and contribute to glaucoma pathogenesis. The manuscript discusses evidence from both animal models and human studies, providing insights into the epigenetic alterations associated with glaucoma onset and progression. Additionally, it discusses the potential of using epigenetic modifications as diagnostic biomarkers and therapeutic targets for more personalized and targeted glaucoma treatment.

Keywords: epigenetics; glaucoma; glaucomatous neurodegeneration; neurodegeneration; neurodegenerative disorder; retinal ganglion cell dysfunction.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. European Glaucoma Society Terminology and Guidelines for Glaucoma, 4th Edition—Chapter 2: Classification and terminology Supported by the EGS Foundation: Part 1: Foreword; Introduction; Glossary; Chapter 2 Classification and Terminology. Br. J. Ophthalmol. 2017;101:73–127. doi: 10.1136/bjophthalmol-2016-EGSguideline.002. - DOI - PMC - PubMed
    1. Tham Y.C., Li X., Wong T.Y., Quigley H.A., Aung T., Cheng C.Y. Global prevalence of glaucoma and projections of glaucoma burden through 2040: A systematic review and meta-analysis. Ophthalmology. 2014;121:2081–2090. doi: 10.1016/j.ophtha.2014.05.013. - DOI - PubMed
    1. Imrie C., Tatham A.J. Glaucoma: The patient’s perspective. Br. J. Gen. Pract. 2016;6:e371–e373. doi: 10.3399/bjgp16X685165. - DOI - PMC - PubMed
    1. Hashemi H., Mohammadi M., Zandvakil N., Khabazkhoob M., Emamian M.H., Shariati M., Fotouhi A. Prevalence and risk factors of glaucoma in an adult population from Shahroud, Iran. J. Curr. Ophthalmol. 2018;31:366–372. doi: 10.1016/j.joco.2018.05.003. - DOI - PMC - PubMed
    1. McMonnies C.W. Glaucoma history and risk factors. J. Optom. 2017;10:71–78. doi: 10.1016/j.optom.2016.02.003. - DOI - PMC - PubMed